Literature DB >> 8848350

Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys.

S D Revak1, T A Merritt, C G Cochrane, G P Heldt, M S Alberts, D W Anderson, A Kheiter.   

Abstract

Studies were conducted to assess the efficacy and safety of a synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome (RDS) in preterm (approximately 80% of normal gestation) infant rhesus monkeys. Surfactant was prepared consisting of the phospholipids dipalmitoylphosphatidyl choline and palmitoyl-oleoyl phosphatidyl glycerol and a synthetic peptide modeled after surfactant protein B (SP-B), "KL4-Surfactant" contained a peptide having the sequence KLLLLKLLLLKLLLLKLLLLK, where "K" is lysine and "L" is leucine. The peptide was selected because it mimics the repeating stretches of hydrophobic residues with intermittent basic hydrophilic residues seen in SP-B. KL4-Surfactant was shown to have biophysical activity assessed as the ability to lower surface tension at an air-liquid interface in a pulsating bubble surfactometer. Thirty premature rhesus monkeys were treated shortly after birth with one dose of KL4-Surfactant. The arterial to alveolar oxygen partial pressure ratio (a/A) was found to rise from a pretreatment level of 0.11 +/- 0.01 (mean +/- SEM), indicative of severe RDS, to 0.40 +/- 0.02 at 12-13 h post-treatment. The improvement in oxygenation persisted throughout the study period, with a mean a/A at 22-23 h of 0.45 +/- 0.07. Chest radiographs and gross and microscopic examination of the lungs all confirmed the reversal of the atelectasis seen before treatment. Animals treated with a dose of 200 mg/kg showed a faster, more consistent, and greater response than did a group treated with an average dose of 127 mg/kg. There was no evidence of toxicity after treatment with the higher dose as demonstrated by physiologic, hematologic, biochemical, and pathologic data. The importance of the peptide in the synthetic surfactant was apparent from the results obtained with a control group of nine premature monkeys treated with a non-peptide-containing surfactant; the a/A of this group was 0.15 +/- 0.03 at nine hours of age as compared with a value of 0.38 +/- 0.02 for 30 comparable animals receiving KL4-Surfactant.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8848350     DOI: 10.1203/00006450-199604000-00025

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  11 in total

1.  A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema.

Authors:  Frank Guarnieri; Jean L Spencer; Edgar C Lucey; Matthew A Nugent; Phillip J Stone
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  Effects of a cationic and hydrophobic peptide, KL4, on model lung surfactant lipid monolayers.

Authors:  J Ma; S Koppenol; H Yu; G Zografi
Journal:  Biophys J       Date:  1998-04       Impact factor: 4.033

3.  The role of surfactant proteins in DPPC enrichment of surface films.

Authors:  E J Veldhuizen; J J Batenburg; L M van Golde; H P Haagsman
Journal:  Biophys J       Date:  2000-12       Impact factor: 4.033

Review 4.  Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future.

Authors:  Smeeta Sardesai; Manoj Biniwale; Fiona Wertheimer; Arlene Garingo; Rangasamy Ramanathan
Journal:  Pediatr Res       Date:  2016-10-05       Impact factor: 3.756

5.  Synthetic surfactant based on analogues of SP-B and SP-C is superior to single-peptide surfactants in ventilated premature rabbits.

Authors:  Andreas Almlén; Frans J Walther; Alan J Waring; Bengt Robertson; Jan Johansson; Tore Curstedt
Journal:  Neonatology       Date:  2010-01-21       Impact factor: 4.035

6.  Biophysical activity of an artificial surfactant containing an analogue of surfactant protein (SP)-C and native SP-B.

Authors:  M Palmblad; J Johansson; B Robertson; T Curstedt
Journal:  Biochem J       Date:  1999-04-15       Impact factor: 3.857

7.  Molecular dynamics study of the lung surfactant peptide SP-B1-25 with DPPC monolayers: insights into interactions and peptide position and orientation.

Authors:  Senthil K Kandasamy; Ronald G Larson
Journal:  Biophys J       Date:  2005-03       Impact factor: 4.033

8.  Pulmonary surfactant model systems catch the specific interaction of an amphiphilic peptide with anionic phospholipid.

Authors:  Hiromichi Nakahara; Sannamu Lee; Osamu Shibata
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

Review 9.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

10.  Effects of anesthesia with isoflurane, ketamine, or propofol on physiologic parameters in neonatal rhesus macaques (Macaca mulatta).

Authors:  Lauren D Martin; Gregory A Dissen; Matthew J McPike; Ansgar M Brambrink
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-05       Impact factor: 1.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.